MARKET

FOLD

FOLD

Amicus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.28
+0.36
+3.02%
After Hours: 12.12 -0.16 -1.30% 17:54 02/26 EST
OPEN
12.03
PREV CLOSE
11.92
HIGH
12.30
LOW
11.68
VOLUME
5.19M
TURNOVER
--
52 WEEK HIGH
25.39
52 WEEK LOW
6.25
MARKET CAP
3.20B
P/E (TTM)
-10.6931
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings
Biotech stocks extended their losses in the week ended Feb. 26 amid continued weakness in the broader market. Earnings came in thick and fast, with a skew of small and midcap companies releasing their quarterly results.
Benzinga · 1d ago
Earnings Preview for Amicus Therapeutics
Amicus Therapeutics (NASDAQ:FOLD) unveils its next round of earnings this Monday, March 01. Get prepared with Benzinga's ultimate preview for Amicus Therapeutics's Q4 earnings. What Are Earnings, Net Income, And Earnings Per Share? Earnings and EPS are use...
Benzinga · 2d ago
Pompe Disease - Pipeline Insight, 2020
Feb 26, 2021 (Heraldkeepers) -- DelveInsight's, "Pompe Disease - Pipeline Insight, 2020," report provides comprehensive insights about 30+ companies and 30+...
Heraldkeepers · 2d ago
45.4% Return Seen to Date on SmarTrend Amicus Therapeut Call (FOLD)
SmarTrend identified a Downtrend for Amicus Therapeut (NASDAQ:FOLD) on January 5th, 2021 at $21.90. In approximately 2 months, Amicus Therapeut has returned 45.42% as of today's recent price of $11.95.
Comtex SmarTrend(R) · 5d ago
Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know
Zacks.com · 6d ago
Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know
Zacks.com · 6d ago
Global Lysosomal Alpha Glucosidase Market Professional Survey, Growth, Shares, Opportunities and Forecast to 2027
Feb 22, 2021 (The Expresswire) -- Global “Lysosomal Alpha Glucosidase Market” forecast 2027; research report analyzed the existing state of the market by...
The Express Wire · 6d ago
Lysosomal Alpha Glucosidase Market classification, Opportunities, Types and Applications, Status and Forecast 2020 to 2027 By Ameco Research
pune, India, Mon, 22 Feb 2021 01:30:23 / Comserve Inc. / -- Lysosomal Alpha Glucosidase market is segmented by Type, and by Application. Players,...
Comserve · 02/22 06:31
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FOLD. Analyze the recent business situations of Amicus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FOLD stock price target is 18.63 with a high estimate of 29.00 and a low estimate of 12.50.
EPS
Institutional Holdings
Institutions: 408
Institutional Holdings: 325.82M
% Owned: 125.03%
Shares Outstanding: 260.59M
TypeInstitutionsShares
Increased
88
17.69M
New
74
7.74M
Decreased
95
22.09M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Chief Executive Officer/Director
John Crowley
President/Chief Operating Officer/Director
Bradley Campbell
Chief Financial Officer
Daphne Quimi
Chief Accounting Officer/Vice President - Finance/Controller
Samantha Prout
Senior Vice President
Simon Jordan
Chief Scientific Officer
Hung Do
Senior Vice President
Jill Weimer
General Counsel/Secretary
Ellen Rosenberg
Other
Jay Barth
Other
David Clark
Lead Director/Independent Director
Michael Raab
Independent Director
Lynn Bleil
Independent Director
Robert Essner
Independent Director
Michael Kelly
Independent Director
Margaret McGlynn
Independent Director
Glenn Sblendorio
Independent Director
Craig Wheeler
Independent Director
Burke Whitman
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About FOLD
Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The Company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.

Webull offers kinds of Amicus Therapeutics, Inc. stock information, including NASDAQ:FOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FOLD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FOLD stock methods without spending real money on the virtual paper trading platform.